Key Points
- Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares at an average price of $98.92, worth approximately $1.98 million, under a pre-arranged Rule 10b5-1 trading plan. He retained 194,309 shares after the transaction.
- Mirum’s latest quarterly results showed revenue of $176.24 million, up 37.9% year over year and above estimates, but its adjusted loss of $1.06 per share was wider than analysts expected.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $137.33, while several major institutional investors recently increased or initiated positions.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $98.92, for a total value of $1,978,400.00. Following the completion of the sale, the chief executive officer owned 194,309 shares in the company, valued at approximately $19,221,046.28. The trade was a 9.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Peetz also recently made the following trade(s):
- On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.27, for a total value of $2,445,400.00.
- On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00.
Mirum Pharmaceuticals Price Performance
Shares of NASDAQ MIRM opened at $98.23 on Wednesday. The stock's 50-day moving average is $110.50 and its two-hundred day moving average is $101.94. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00. The company has a market cap of $6.38 billion, a price-to-earnings ratio of -6.75 and a beta of 0.52.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals's revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.12) EPS. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.24 EPS for the current fiscal year.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. Janus Henderson Group PLC boosted its holdings in shares of Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock valued at $479,050,000 after buying an additional 1,067,722 shares in the last quarter. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company's stock valued at $169,354,000 after buying an additional 797,088 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock valued at $57,965,000 after buying an additional 672,118 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Mirum Pharmaceuticals during the 2nd quarter worth $78,434,000.
Analyst Ratings Changes
MIRM has been the topic of several analyst reports. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Citigroup reissued an "outperform" rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a report on Thursday, August 6th. Royal Bank Of Canada reduced their price objective on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, TD Cowen decreased their price objective on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $137.33.
View Our Latest Research Report on MIRM
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
